AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

75 76 Next >

TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

November 08, 2024

From AstraZeneca

Via Business Wire

AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024

November 07, 2024

From AstraZeneca

Via Business Wire

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say ↗

November 05, 2024

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.

Via Benzinga

Why Is AstraZeneca Stock Sinking On Tuesday? ↗

November 05, 2024

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock falls around 7%

Via Benzinga

Smart Money Is Betting Big In AZN Options ↗

November 04, 2024

Via Benzinga

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug ↗

November 04, 2024

AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety, tolerability, and convenient dosing.

Via Benzinga

3 Magnificent Stocks Under $100 to Buy in November ↗

November 03, 2024

The price could be right for these stocks.

Via The Motley Fool

3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever ↗

October 31, 2024

In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to disrupt themselves.

Via The Motley Fool

Monopar Therapeutics Skyrockets 400% on Licensing Deal

October 25, 2024

Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.

Via MarketBeat

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast ↗

October 25, 2024

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%.

Via Benzinga

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder ↗

October 24, 2024

Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.

Via Benzinga

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain ↗

October 11, 2024

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain.

Via Benzinga

Topics Lawsuit

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks ↗

October 08, 2024

Investing in the most popular players in the space isn't the only valid approach.

Via The Motley Fool

Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge ↗

October 07, 2024

Via Benzinga

Topics Stocks

Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher ↗

October 07, 2024

Via Benzinga

US Stocks Open Lower; Dow Tumbles Over 150 Points ↗

October 07, 2024

Via Benzinga

Topics Stocks

AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline ↗

October 07, 2024

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in a...

Via Benzinga

AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

October 07, 2024

From AstraZeneca

Via Business Wire

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses ↗

October 04, 2024

Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...

Via Benzinga

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review ↗

October 03, 2024

AstraZeneca's Calquence receives FDA Priority Review for previously untreated mantle cell lymphoma, showing promising Phase 3 trial results in reducing disease progression by 27%. An FDA decision is...

Via Benzinga

CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma

October 03, 2024

From AstraZeneca

Via Business Wire

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗

October 01, 2024

HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...

Via Benzinga

Topics Economy

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

October 01, 2024

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Via News Direct

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

October 01, 2024

From AstraZeneca

Via Business Wire

Is Summit Therapeutics Stock a Buy? ↗

September 30, 2024

Its alliance with a successful foreign biotech could be decisive for the stock.

Via The Motley Fool

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.